Alofisel for Crohn’s Fistulas Receives EMA Recommendation for Marketing Authorization in EU

Alofisel for Crohn’s Fistulas Receives EMA Recommendation for Marketing Authorization in EU
TiGenix received a European Medicines Agency (EMA) recommendation for the marketing authorization of Alofisel (darvadstrocel, Cx601) as an advanced therapy medicinal product (ATMP) for the treatment of complex perianal fistulas in people with Crohn’s disease. Perianal fistulas occur when an abnormal opening develops between the rectum and the outside of the body. It can lead to incontinence and sepsis (infection in the blood). In Crohn’s disease, perianal fistulas develop as a consequence of patients' inflammatory bowel disease. The active substance in Alofisel, darvadstrocel, contains expanded adipose stem cells that impair proliferation of lymphocytes (immune system cells) and reduce the release of pro-inflammatory molecules at inflammation sites. This immuno-regulatory activity resolves inflammation and allows the tissues around the fistula tract to heal. The marketing authorization recommendation follows the results of the Phase 3 ADMIRE-CD clinical trial (NCT01541579) involving 278 participants. After a 24-week treatment, 49.5 percent of the patients who received Alofisel were in remission, compared to one-third of the patients receiving placebo. An extended 104-week ongoing follow-up study so far supports this achievement. The effect is considered clinically meaningful because other treatment options for fistulas have failed so far, as there is only a moderate difference between treatment groups. Side
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *